Literature DB >> 29890267

Sustained delivery of siRNA/mesoporous silica nanoparticle complexes from nanofiber scaffolds for long-term gene silencing.

Coline Pinese1, Junquan Lin2, Ulla Milbreta2, Mingqiang Li3, Yucai Wang4, Kam W Leong3, Sing Yian Chew5.   

Abstract

A low toxicity and efficient delivery system is needed to deliver small interfering RNAs (siRNA) in vitro and in vivo. The use of mesoporous silica nanoparticles (MSN) is becoming increasingly common due to its biocompatibility, tunable pore size and customizable properties. However, bolus delivery of siRNA/MSN complexes remains suboptimal, especially when a sustained and long-term administration is required. Here, we utilized electrospun scaffolds for sustained delivery of siRNA/MSN-PEI through surface adsorption and nanofiber encapsulation. As a proof-of-concept, we targeted collagen type I expression to modulate fibrous capsule formation. Surface adsorption of siRNA/MSN-PEI provided sustained availability of siRNA for at least 30 days in vitro. As compared to conventional bolus delivery, such scaffold-mediated transfection provided more effective gene silencing (p < 0.05). On the contrary, a longer sustained release was attained (at least 5 months) when siRNA/MSN-PEI complexes were encapsulated within the electrospun fibers. In vivo subcutaneous implantation and biodistribution analysis of these scaffolds revealed that siRNA remained localized up to ∼290 μm from the implants. Finally, a fibrous capsule reduction of ∼45.8% was observed after 4 weeks in vivo as compared to negative scrambled siRNA treatment. Taken together, these results demonstrate the efficacy of scaffold-mediated sustained delivery of siRNA/MSN-PEI for long-term non-viral gene silencing applications. STATEMENT OF SIGNIFICANCE: The bolus delivery of siRNA/mesoporous silica nanoparticles (MSN) complexes shows high efficiency to silence protein agonists of tumoral processes as cancer treatments. However, in tissue engineering area, scaffold mediated delivery is desired to achieve a local and sustained release of therapeutics. We showed the feasibility and the efficacy of siRNA/MSN delivered from electrospun scaffolds through surface adsorption and nanofiber encapsulation. We showed that this method enhances siRNA transfection efficiency and sustained targeted proteins silencing in vitro and in vivo. As a proof of concept, in this study, we targeted collagen type I expression to modulate fibrous capsule formation. However this platform can be applied to the release and transfection of siRNA or miRNA in cancer and tissue engineering applications.
Copyright © 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Electrospinning; Foreign body reaction; Gene silencing; Host-implant integration

Mesh:

Substances:

Year:  2018        PMID: 29890267     DOI: 10.1016/j.actbio.2018.05.054

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  21 in total

1.  Mesoporous Silica Nanoparticles as Carriers for Biomolecules in Cancer Therapy.

Authors:  Berrin Küçüktürkmen; Jessica M Rosenholm
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors.

Authors:  Devan L Puhl; Anthony R D'Amato; Ryan J Gilbert
Journal:  Brain Res Bull       Date:  2019-06-05       Impact factor: 4.077

Review 3.  Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines.

Authors:  Chiara Rinoldi; Seyed Shahrooz Zargarian; Pawel Nakielski; Xiaoran Li; Anna Liguori; Francesca Petronella; Dario Presutti; Qiusheng Wang; Marco Costantini; Luciano De Sio; Chiara Gualandi; Bin Ding; Filippo Pierini
Journal:  Small Methods       Date:  2021-07-28

Review 4.  Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?

Authors:  María Vallet-Regí; Ferdi Schüth; Daniel Lozano; Montserrat Colilla; Miguel Manzano
Journal:  Chem Soc Rev       Date:  2022-07-04       Impact factor: 60.615

Review 5.  Electrospun-Fibrous-Architecture-Mediated Non-Viral Gene Therapy Drug Delivery in Regenerative Medicine.

Authors:  Elena Cojocaru; Jana Ghitman; Raluca Stan
Journal:  Polymers (Basel)       Date:  2022-06-29       Impact factor: 4.967

6.  Combination of Nucleic Acid and Mesoporous Silica Nanoparticles: Optimization and Therapeutic Performance In Vitro.

Authors:  Ridhima Juneja; Hemapriyadarshini Vadarevu; Justin Halman; Mubin Tarannum; Lauren Rackley; Jacob Dobbs; Jose Marquez; Morgan Chandler; Kirill Afonin; Juan L Vivero-Escoto
Journal:  ACS Appl Mater Interfaces       Date:  2020-08-18       Impact factor: 9.229

7.  Endosomal signaling of delta opioid receptors is an endogenous mechanism and therapeutic target for relief from inflammatory pain.

Authors:  Nestor N Jimenez-Vargas; Jing Gong; Matthew J Wisdom; Dane D Jensen; Rocco Latorre; Alan Hegron; Shavonne Teng; Jesse J DiCello; Pradeep Rajasekhar; Nicholas A Veldhuis; Simona E Carbone; Yang Yu; Cintya Lopez-Lopez; Josue Jaramillo-Polanco; Meritxell Canals; David E Reed; Alan E Lomax; Brian L Schmidt; Kam W Leong; Stephen J Vanner; Michelle L Halls; Nigel W Bunnett; Daniel P Poole
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-16       Impact factor: 11.205

Review 8.  Electrospun Nanofibers for Cancer Therapy.

Authors:  Huanhuan Luo; Tianyang Jie; Li Zheng; Chenglong Huang; Gang Chen; Wenguo Cui
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

9.  UCN-SiO2-GO: a core shell and conjugate system for controlling delivery of doxorubicin by 980 nm NIR pulse.

Authors:  Pradip Paik; K Santhosh Kumar; Monami Das Modak; Koushi Kumar U; Somedutta Maity
Journal:  RSC Adv       Date:  2018-11-07       Impact factor: 4.036

10.  In vivo targeted delivery of nucleic acids and CRISPR genome editors enabled by GSH-responsive silica nanoparticles.

Authors:  Yuyuan Wang; Pawan K Shahi; Xiuxiu Wang; Ruosen Xie; Yi Zhao; Min Wu; Seth Roge; Bikash R Pattnaik; Shaoqin Gong
Journal:  J Control Release       Date:  2021-06-23       Impact factor: 11.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.